5) Liver Health: Addressing Non-Alcoholic Fatty Liver Disease (NAFLD) GLP-1 medications are demonstrating efficacy in managing NAFLD, a growing public health concern often associated with obesity, insulin resistance, and Type 2 diabetes
Reduced renal clearance, increased elimination half-life ( t ), and high maximum plasma drug concentration ( C max ) values of antidiabetic drugs may lead to high and prolonged drug exposure [11,12,13,14,15,16,17]
Do not use this product as a substitute for a varied diet, appropriate medical care, or treatment recommended by a healthcare professional
PRESCRIBER INFORMATION Our suspension is compounded exclusively with Rybelsus, an FDA-approved tablet
No: CL-SGTD-106 CAS No: 104091-08-9 Mol